Mineralys Therapeutics, Inc. (MLYS) Stock
MLYS has an Alpha Score of 17 out of 100 (poor), computed on Nov 9, 2026 from 2 of 4 sub-scores. 5 of the hedge funds AlphaScala tracks reported MLYS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $32.96M. Company insiders reported 0 open-market buys and 5 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
What is MLYS's Alpha Score?
How it works →Alpha Score of 17 reflects poor overall profile with poor momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 9, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own MLYS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 1.22M | $32.96M | +133% |
| Citadel Ken Griffin | 468K | $12.62M | -22% |
| Renaissance Technologies Jim Simons (founder) | 378K | $10.21M | -1% |
| D.E. Shaw David Shaw | 353K | $9.52M | -60% |
| Marshall Wace | 18K | $485.6K | +100% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Mineralys Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 30, 26 | Congleton Jon | Chief Executive Officer | SELL | 75.0K | $1.9M |
| Sep 22, 26 | Slingsby Brian Taylor | Director | SELL | 104.3K | $3.0M |
| Sep 21, 26 | Warren Eric | Chief Commercial Officer | SELL | 7.4K | $209K |
| Sep 15, 26 | Karydas Daphne | Director | SELL | 3.0K | $86K |
| Aug 21, 26 | Warren Eric | Chief Commercial Officer | SELL | 7.4K | $193K |
| Aug 10, 26 | Rodman David Malcom | Chief Medical Officer | SELL | 2.2K | $59K |
| Jul 21, 26 | Warren Eric | Chief Commercial Officer | SELL | 7.4K | $200K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are MLYS's key statistics?
Key statistics as of Nov 1, 2026
MLYS price chart
Powered by TradingViewWhat does Mineralys Therapeutics, Inc. do?
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cardio-renal-metabolic syndrome diseases, particularly those driven by dysregulated aldosterone. Its lead product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor initially aimed at treating uncontrolled hypertension and resistant hypertension in patients not achieving blood pressure goals despite multiple antihypertensive medications. The company addresses unmet needs in hypertension, chronic kidney disease, obstructive sleep apnea, and related conditions where elevated aldosterone plays a key role, offering a novel mechanism to lower aldosterone levels by inhibiting the CYP11B2 enzyme. Mineralys Therapeutics, Inc. emphasizes precision in treatment, targeting patients with indicators like obesity that suggest aldosterone dependency. Led by an experienced management team and supported by expert scientific and board advisors in cardiovascular and renal diseases, the company advances its pipeline through clinical development. Founded in 2019 and headquartered in Radnor, Pennsylvania, Mineralys Therapeutics, Inc. plays a significant role in the biotechnology sector by innovating solutions for prevalent cardiometabolic disorders affecting millions worldwide.